Compare Tesla, Inc. (TSLA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Tesla, Inc. trades at $382.7 (market cap $1.48T), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Tesla, Inc. is far larger — about 146.4× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tesla, Inc. for 88 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TSLA | XBI | |
|---|---|---|
Market Cap | $1.48T | $10.11B |
Volume | 28,215,427 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $489.88 | $169.55 |
52-Week Low | $298.16 | $104.99 |
Typical Hold Time | 88 Days | 38 Days |
Enterprise Value | $1.45T | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla trades at $375.03, down 0.68% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs. $0.50 expected) but beat expectations in the previous two quarters. Revenue declined to $94.83B in 2025 with net income margin compressing to 4%. Recent news highlights regulatory approval for driver assistance software in Europe and a potential cheaper EV launch.
Tesla faces near-term headwinds from slowing auto growth and elevated valuations (P/E 347), but long-term optimism centers on autonomous driving and energy segments. Analyst consensus price target of $441.36 suggests 18% upside, though execution risks and competition remain key concerns for investors.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
